Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional
OpenUpdated: Oct 30, 2025
Summary
The grant aims to develop a physiologically based pharmacokinetic (PBPK) model to establish mechanistic in vitro in vivo correlations for long-acting injectables (LAIs), focusing on crystalline suspensions and polymer-based implants. Eligible applicants include various nonprofit organizations, educational institutions, government entities, and for-profit organizations, including small businesses. Application details are not specified, but interested parties can contact the grantor via email at Terrin.Brown@fda.hhs.gov for more information.
Full Description
Description
The objective of this research proposal is to develop physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro in vivo correlations (IVIVCs) for two major types of long acting injectables (LAIs) such as crystalline suspensions and polymer-based implants by considering their distinct characteristics. The goal of the project is to develop a bottom-up mechanistic PBPK model for these two LAI categories by accounting for the influence of critical formulation attributes of each LAI drug product type to predict its in vivo release mechanism. The model formulation parameters and relevant physiology should be informed with suitable in vitro and in vivo experiments. A suitable preclinical animal model can be used to validate the PBPK model based IVIVCs for both LAI suspensions and polymer based implants.
...The use of PBPK modelling provides a unique opportunity to understand how the physicochemical properties of drug molecules/polymer, implant specific properties, critical formulation attributes, and physiology, among other things, influence the in vivo release mechanisms of LAI drug products and their disposition characteristics. Moreover, once developed, a mechanistic PBPK model can help to define the 'safe space' for critical formulation attributes relevant to the reference listed drug (RLD) product, explain sources of PK variability and extrapolate predictions to human subjects by leveraging animal model data and by accounting for species-specific physiological differences.
Eligibility
Eligible applicants
Nonprofit
- Nonprofits non-higher education with 501(c)(3)
- Nonprofits non-higher education without 501(c)(3)
- Other Native American tribal organizations
Education
- Independent school districts
- Public and state institutions of higher education
- Private institutions of higher education
Government
- County governments
- Federally recognized Native American tribal governments
- Public and Indian housing authorities
- State governments
- Special district governments
- City or township governments
Miscellaneous
- Other
Business
- For-profit organizations other than small businesses
- Small businesses
Additional information
Grantor contact information
Description
Terrin.Brown@fda.hhs.gov
Recommended Resource
Grant Writing Services on Fiverr
Top PickStruggling with grant applications? Get expert help from professional freelance writers on Fiverr — from research and proposal drafts to compliance review and submission. Secure funding faster with proven talent.